281 related articles for article (PubMed ID: 37901297)
1. New Treatment Options for Refractory/Resistant CMV Infection.
Walti CS; Khanna N; Avery RK; Helanterä I
Transpl Int; 2023; 36():11785. PubMed ID: 37901297
[TBL] [Abstract][Full Text] [Related]
2. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
Monday LM; Keri V; Chandrasekar PH
Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
[TBL] [Abstract][Full Text] [Related]
3. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
Razonable RR
Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
[TBL] [Abstract][Full Text] [Related]
4. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
5. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
[TBL] [Abstract][Full Text] [Related]
6. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Frange P; Leruez-Ville M
Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
[TBL] [Abstract][Full Text] [Related]
7. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
[TBL] [Abstract][Full Text] [Related]
8. Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection.
Ouellette CP
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366468
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
10. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
Valencia Deray KG; Danziger-Isakov LA; Downes KJ
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
[TBL] [Abstract][Full Text] [Related]
11. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients.
Imlay HN; Kaul DR
Clin Infect Dis; 2021 Jul; 73(1):156-160. PubMed ID: 33197929
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium.
Khawaja F; Spallone A; Kotton CN; Chemaly RF
Clin Microbiol Infect; 2023 Jan; 29(1):44-50. PubMed ID: 35843567
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Bruminhent J; Rotjanapan P; Watcharananan SP
Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.
Mehta Steinke SA; Alfares M; Valsamakis A; Shoham S; Arav-Boger R; Lees L; Ostrander D; Forman MS; Shedeck A; Ambinder RF; Jones RJ; Avery RK
Transpl Infect Dis; 2021 Jun; 23(3):e13521. PubMed ID: 33220125
[TBL] [Abstract][Full Text] [Related]
15. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Meesing A; Razonable RR
Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
[TBL] [Abstract][Full Text] [Related]
16. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
17. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in cytomegalovirus infection management in solid organ transplant recipients.
Grossi PA; Peghin M
Curr Opin Organ Transplant; 2024 Apr; 29(2):131-137. PubMed ID: 38288947
[TBL] [Abstract][Full Text] [Related]
19. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
Ortiz F; Lempinen M; Aaltonen S; Koivuviita N; Helanterä I
Clin Transplant; 2022 Feb; 36(2):e14537. PubMed ID: 34797574
[TBL] [Abstract][Full Text] [Related]
20. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
